An end-to-end efficacy evaluation approach for identifying progression risk after epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) therapy in patients with stage IV EGFR variant–positive non–small cell lung cancer (NSCLC) is lacking. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.